share_log

Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target

Benzinga ·  Apr 25 10:17

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment